Somite Therapeutics Achieves Key Milestone with FDA Orphan Drug and Rare Pediatric Disease Designations for SMT-M01 in Duchenne Muscular Dystrophy
Somite Therapeutics has announced a major breakthrough in the fight against Duchenne Muscular Dystrophy (DMD), securing both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the FDA for their lead therapeutic candidate, SMT-M01. These designations are critical in the development of therapies targeting rare diseases, offering benefits such as tax credits for […]